Judge Dismisses Antitrust Suit Claiming Novartis Improperly Listed Entresto Patent in FDA Orange Book
核心洞察
US District Judge Lewis Liman dismissed a proposed class action alleging Novartis improperly listed a patent in the FDA Orange Book to delay generic Entresto competition.
The Iron Workers Local 580 Insurance Fund claimed the listing delayed generic entry by at least six months and inflated prices for Entresto purchasers.
Judge Liman agreed with Novartis that the disputed patent was properly listed, removing the basis for the purchasers' generic-delay theory.
A federal judge has dismissed a proposed class action accusing Novartis Pharmaceuticals Corporation of improperly listing a patent in the US Food and Drug Administration's Orange Book to delay generic competition for its heart failure (搜索) drug Entresto.
US District Judge Lewis Liman dismissed the lawsuit brought by the Iron Workers Local 580 Insurance Fund on behalf of Entresto purchasers who alleged they paid inflated prices because of the disputed patent listing. The case is Iron Workers Local 580 Insurance Fund v. Novartis Pharmaceuticals Corporation in the US District Court for the Southern District of New York.
The Orange Book dispute at the centre of the case
The case centred on the FDA's Orange Book, which identifies approved medicines and patents that manufacturers say cover those products. Patent listings can affect when generic manufacturers are able to enter the market and can therefore become the basis of competition-law disputes.
The union fund, which filed suit in August 2025, accused Novartis of improperly listing US Patent No. 8,101,659 in the Orange Book, which it said extended the drugmaker's ability to charge monopoly prices for Entresto by more than five months. According to the lawsuit, the listing delayed generic competition by at least six months.
The purchasers alleged that Novartis improperly characterised the patent as covering Entresto even though, in their view, the patent covered the drug's component ingredients rather than the particular form in which those ingredients are combined. The union argued that Novartis had abused the Orange Book process because Entresto combines two active ingredients, sacubitril and valsartan, as a "complex," while the '659 patent more generally covers a 1-to-1 ratio of those ingredients.
The purchasers alleged that Novartis generated more than $2 billion in US Entresto sales during the period of delayed generic entry and that buyers consequently paid higher prices than they would have faced with earlier generic competition.
Judge rejects the generic-delay theory
Judge Liman rejected that central argument. He agreed with Novartis that the disputed patent was properly listed in the Orange Book, defeating the insurance fund's claim that the listing had been improper. The ruling therefore removed the basis for the purchasers' generic-delay theory as pleaded in the case.
The decision is significant because Orange Book disputes can extend beyond conventional patent litigation between branded pharmaceutical companies and generic manufacturers. Purchasers may also pursue claims where they allege that an improper listing delayed competition and caused them to overpay for medicines.
Those claims depend heavily on the underlying patent-listing question. If a patent was entitled to be listed, a purchaser cannot simply treat the resulting period of exclusivity as unlawful anticompetitive conduct.
The ruling does not amount to a broader finding that every element of Novartis's Entresto patent strategy was lawful. It addresses the specific purchaser claim before Liman and his conclusion that the patent challenged in that lawsuit was properly included in the Orange Book.
Commercial stakes as generics erode Entresto sales
Entresto, a combination of sacubitril and valsartan used to treat heart failure (搜索), has been Novartis's best-selling medicine. The commercial significance of generic competition is already evident.
Novartis reported that Entresto sales fell 42% to $1.31 billion in the first quarter of 2026 after US patents expired and generic versions entered the market. The medicine accounted for 14% of the company's sales in the previous year.
For pharmaceutical companies and their legal advisers, the case demonstrates how patent-listing decisions can create potential exposure beyond intellectual-property litigation. A disputed Orange Book entry can become the foundation for purchaser claims seeking damages for alleged overcharges.
For purchasers, however, establishing that generic competition was delayed is not enough on its own. A viable competition claim also requires a legally sustainable basis for treating the conduct that caused the alleged delay as improper.
The Novartis ruling therefore highlights the close relationship between pharmaceutical patent law and antitrust litigation. Where a generic-delay claim depends on an allegedly improper Orange Book listing, the interpretation and scope of the patent itself can determine whether the wider competition case survives.